Amicus Therapeutics, Inc. (FOLD)
| Market Cap | 2.45B |
| Revenue (ttm) | 266.76M |
| Net Income (ttm) | -253.57M |
| Shares Out | 264.37M |
| EPS (ttm) | -0.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $9.37 |
| Previous Close | $9.22 |
| Change ($) | 0.15 |
| Change (%) | 1.63% |
| Day's Open | 9.23 |
| Day's Range | 9.06 - 9.42 |
| Day's Volume | 1,774,568 |
| 52-Week Range | 8.83 - 25.39 |
Amicus (FOLD) reports a wider Q1 loss and sales miss estimates.
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -8.70% and -7.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 28.57% over the past year to ($0.25), whic...
Galafold ® (migalastat) Performance Reflects Continued Strong Adoption in All Key Global Regions; On-Track to Achieve Revenue Guidance of $300M-$315M
PHILADELPHIA, May 07, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the foll...
Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme
Amicus Therapeutics (FOLD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics Inc (NASDAQ: FOLD) has completed a Type B Pre-Biologics License Application (BLA) meeting with the FDA for AT-GAA (cipaglucosidase alfa co-administered with miglustat) for Pompe dise...
Great Place to Work® Certification in the United Kingdom, Spain, Italy and Germany Great Place to Work® Certification in the United Kingdom, Spain, Italy and Germany
PHILADELPHIA, April 26, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 10, 2021 at 8:30 a....
Investors cheered an analyst's upgrade of the biotech stock.
Amicus (FOLD) reports a wider-than-expected Q4 loss but sales beat estimates.
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -12.50% and 0.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Amicus Therapeutics (NASDAQ:FOLD) moved higher by 0.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 22.86% over the past year to ($0.2...
Amicus Therapeutics (NASDAQ:FOLD) unveils its next round of earnings this Monday, March 01. Get prepared with Benzinga's ultimate preview for Amicus Therapeutics's Q4 earnings.
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics said Thursday its rare-disease treatment failed to outperform a standard drug on one key measure in a Phase 3 test. In response, FOLD stock plunged on Friday.
Amicus Therapeutics said Thursday its rare-disease treatment failed to outperform a standard drug on one key measure in a Phase 3 test. In response, FOLD stock plunged on Friday.
John Crowley, Amicus Therapeutics, discusses drug trial results for Pompe disease
CNBC Meg Tirrell talks with Amicus Therapeutics CEO John Crowley about trial results for a drug to treat Pompe disease. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen ...
Amicus releases phase 3 results in Pompe disease trial
CNBC's senior health and science reporter Meg Tirrell reports Amicus showed results in its phase 3 trial to address Pompe disease. The drug showed it can help people walk and significantly slowed the ra...
Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021
Initial Data Suggest Early Signs of Disease Stabilization in Children with Fatal Neurologic Disease
Amicus Optimized Transgene Show Greater Substrate Reduction than Wild Type Construct Across All Tissues and Doses
Investors need to pay close attention to Amicus Therapeutics (FOLD) stock based on the movements in the options market lately.
CRANBURY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines f...
CRANBURY, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the 39th Annual J.P. Morg...
The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
Biopharma stocks are risky investment bets that sway wildly in reaction to catalytic events. Binary events scheduled for Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Sarepta Therapeutics Inc (NASDAQ: SR...
Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
CRANBURY, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines f...
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Amicus (FOLD) initiates a rolling biologics license application (BLA) submission to the FDA for AT-GAA, for the treatment of late onset Pompe disease.
On Track for Completing the BLA Submission in 1H2021
The shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) are up 1.3% at $22.69 at last check, after hitting a Nov. 18, all-time-high of $23.19.
CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Evercore...
Amicus (FOLD) reports a wider-than-expected loss but sales beat estimates in the third quarter of 2020.
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q3 2020 Results - Earnings Call Transcript
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -10.00% and 3.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
CRANBURY, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present at the Credit Suisse 29th An...
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRANBURY, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at ...
Choosing breakout stocks is one of the most favored methods for those utilizing an active investing approach since this strategy promises superlative returns.
Data Continue to Support Meaningful Effect on Motor and Language Function in Children with Fatal Neurologic Disease Data Continue to Support Meaningful Effect on Motor and Language Function in Children ...
Amicus is making progress on all fronts and the progress is not fully reflected in the company's valuation.
Additional Phase 1/2 Data to be Presented at the Child Neurology Society Annual Meeting in October Additional Phase 1/2 Data to be Presented at the Child Neurology Society Annual Meeting in October
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
CRANBURY, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at th...
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2020 Results - Earnings Call Transcript
Amicus (FOLD) posts a narrower-than-expected loss, while sales beat estimates in the second quarter of 2020.
About FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and ... [Read more...]
| Industry Biotechnology | IPO Date May 31, 2007 |
| CEO John Crowley | Employees 483 |
| Stock Exchange NASDAQ | Ticker Symbol FOLD |
Financial Performance
In 2020, FOLD's revenue was $260.89 million, an increase of 43.16% compared to the previous year's $182.24 million. Losses were -$276.85 million, -22.32% less than in 2019.
Analyst Forecasts
According to 10 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price forecast is 17.59, which is an increase of 87.73% from the latest price.